• +55 (48) 3261-2856
  • contato@cienp.org.br

Autor: cienp

Novartis trial validates inflammasome as chronic disease driver

The dramatic finding that an antibody that inhibits interleukin-1b (IL-1b) can reduce the risk of heart attack and stroke is the first clinical evidence that tackling the inflammatory component of cardiovascular disease can benefit patients. Para acessar a publicação na íntegra clique  aqui   Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 893  …

Speed and oversight: FDA Commissioner Gottlieb acts on pledges

In late August, in a rare tide of bipartisan support, the US Congress passed legislation to reauthorize user fee programs for the next five years… Para acessar a publicação na íntegra clique  aqui   Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017…

First metabolic oncology inhibitor gets FDA green light, with record price tag

On August 1, the US Food and Drug Administration (FDA) granted full approval to an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor to treat relapsed or refractory acute myelogenous leukemia (AML)… Para acessar a publicação na íntegra clique  aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017…

NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges

There is a chasm in the path from basic biomedical research discoveries to their clinical application owing to inadequate funding for support of proof-of-conceptor validation studies for early-stage development of new technologies… Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 16 | OCTOBER 2017 | 1 Para acessar a publicação na íntegra clique  aqui…

Anti-inflammatory drug cuts risk of heart disease — and cancer

After years of trying, researchers have finally shown that a targeted anti-inflammatory agent can guard against life-threatening plaque ruptures in heart attack survivors who remain at risk of further vascular events despite well-controlled lipid levels… Fonte: Nature Reviews Drug Discovery | Published online 29 Sep 2017 Para acessar a publicação na íntegra clique  aqui…

Bispecific antibody pipeline moves beyond oncology

The FDA is currently reviewing Roche’s bispecific antibody emicizumab for the treatment of haemophilia A… Fonte: Nature Reviews Drug Discovery | Published online 29 Sep 2017 Para acessar a publicação na íntegra clique  aqui…

FDA approves first CAR T therapy

The FDA gave the green light to Novartis’s tisagenlecleucel for the treatment of acute lymphoblastic leukaemia (ALL), marking a historic approval for a first-in-modality chimeric antigen receptor (CAR) T cell therapy… Fonte: Nature Reviews Drug Discovery | Published online 29 Sep 2017 Para acessar a publicação na íntegra clique  aqui…

CIEnP organiza evento em parceria com a Academia Brasileira de Ciências e EMBRAPII para discutir inovação tecnológica em Fármacos e Medicamentos.

O evento ocorreu no dia 26 de setembro passado e contou com a presença de mais de 60 pessoas, incluindo o presidente da Academia Brasileira de Ciências, Professor Luiz Davidovich, o Vice Presidente da ABC Professor João Fernandes G. de Oliveira , o Diretor Presidente da Embrapii Professor Jorge A. Guimarães, O secretario de Inovação do MCTIC, professor Álvaro Prata, o Diretor de Inovação da FINEP Victor Odorcyk, a diretora do Departamento de Ciência e Tecnologia – DECIT do Ministério…

Go-ahead for first anti-IL-23 mAb to treat psoriasis

On July 13, the US Food and Drug Administration (FDA) approved Tremfya (guselkumab) to treat moderate to severe plaque psoriasis. Tremfya, developed by Johnson & Johnson’s subsidiary Janssen, of Beers, Belgium, is the first and only human monoclonal antibody (mAb) that selectively blocks… Fonte: VOLUME 35 NUMBER 9 SEPTEMBER 2017 NATURE BIOTECHNOLOGY Para acessar a publicação na íntegra clique  aqui…